Onyx Targeted In Shareholder Suit Over $10.4B Amgen Deal
By Stewart Bishop ( August 29, 2013, 5:56 PM EDT) -- Onyx Pharmaceuticals Inc. and its top brass on Thursday were hit with a shareholder class action alleging breach of fiduciary duty for allowing the drugmaker to be acquired by biotechnology mammoth Amgen Inc. for a lowballed price of $10.4 billion....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.